Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
86.12 USD | -0.86% | +3.58% | +9.32% |
Dec. 12 | UBS Adjusts Price Target on Oxford Industries to $80 From $81, Keeps Neutral Rating | MT |
Dec. 12 | Stocks Decline Pre-Bell Ahead of Latest PPI Report; Asia, Europe Rise | MT |
Fiscal Period: February | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | 6.89 | -2.26 | 10.85 | 12.74 | 10.54 | |||||
Return on Total Capital | 8.91 | -2.72 | 13.41 | 15.73 | 12.9 | |||||
Return On Equity % | 13.6 | -20.48 | 28.75 | 31.16 | 10.87 | |||||
Return on Common Equity | 13.6 | -20.48 | 28.75 | 31.16 | 10.87 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 56.83 | 55.54 | 61.06 | 62.69 | 62.97 | |||||
SG&A Margin | 49.51 | 61.73 | 48.68 | 48.31 | 50.91 | |||||
EBITDA Margin % | 12.23 | 0.77 | 17.35 | 18.87 | 16.35 | |||||
EBITA Margin % | 8.75 | -4.43 | 13.93 | 15.93 | 13.21 | |||||
EBIT Margin % | 8.64 | -4.58 | 13.86 | 15.5 | 12.27 | |||||
Income From Continuing Operations Margin % | 6.1 | -12.78 | 11.5 | 11.74 | 3.86 | |||||
Net Income Margin % | 6.1 | -12.78 | 11.5 | 11.74 | 3.86 | |||||
Net Avail. For Common Margin % | 6.1 | -12.78 | 11.5 | 11.74 | 3.86 | |||||
Normalized Net Income Margin | 5.33 | -3.03 | 8.61 | 9.55 | 7.43 | |||||
Levered Free Cash Flow Margin | 7.23 | 6.46 | 12.8 | 3.3 | 8.79 | |||||
Unlevered Free Cash Flow Margin | 7.27 | 6.59 | 12.82 | 3.41 | 9 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 1.28 | 0.79 | 1.25 | 1.32 | 1.37 | |||||
Fixed Assets Turnover | 3.35 | 1.72 | 3.08 | 3.69 | 3.58 | |||||
Receivables Turnover (Average Receivables) | 18 | 17.56 | 36.86 | 38.9 | 31.64 | |||||
Inventory Turnover (Average Inventory) | 3.1 | 2.41 | 3.69 | 3.12 | 3.06 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 1.62 | 1.32 | 1.77 | 1.23 | 1.22 | |||||
Quick Ratio | 0.63 | 0.58 | 1.17 | 0.27 | 0.38 | |||||
Operating Cash Flow to Current Liabilities | 0.69 | 0.43 | 0.88 | 0.47 | 1.02 | |||||
Days Sales Outstanding (Average Receivables) | 20.22 | 20.73 | 9.87 | 9.36 | 11.73 | |||||
Days Outstanding Inventory (Average Inventory) | 117.49 | 150.75 | 98.74 | 116.75 | 121.04 | |||||
Average Days Payable Outstanding | 56.22 | 81.73 | 63 | 50.73 | 64.1 | |||||
Cash Conversion Cycle (Average Days) | 81.5 | 89.74 | 45.62 | 75.37 | 68.67 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 64.72 | 74.15 | 51.36 | 74.35 | 60.18 | |||||
Total Debt / Total Capital | 39.29 | 42.58 | 33.93 | 42.64 | 37.57 | |||||
LT Debt/Equity | 55.22 | 59.14 | 39.3 | 61.07 | 48.67 | |||||
Long-Term Debt / Total Capital | 33.52 | 33.96 | 25.96 | 35.03 | 30.38 | |||||
Total Liabilities / Total Assets | 48.85 | 53.13 | 46.99 | 53.2 | 48.91 | |||||
EBIT / Interest Expense | 77.96 | -16.92 | 167.64 | 71.75 | 31.95 | |||||
EBITDA / Interest Expense | 190.64 | 49.2 | 308.46 | 121.48 | 62.28 | |||||
(EBITDA - Capex) / Interest Expense | 160.58 | 34.94 | 274.68 | 106.17 | 50 | |||||
Total Debt / EBITDA | 1.44 | 3.02 | 0.9 | 1.12 | 0.9 | |||||
Net Debt / EBITDA | 1.22 | 2.35 | 0.18 | 1.09 | 0.88 | |||||
Total Debt / (EBITDA - Capex) | 1.71 | 4.25 | 1.01 | 1.28 | 1.12 | |||||
Net Debt / (EBITDA - Capex) | 1.45 | 3.31 | 0.2 | 1.25 | 1.09 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | 1.38 | -33.31 | 52.51 | 23.59 | 11.33 | |||||
Gross Profit, 1 Yr. Growth % | 1.01 | -34.83 | 67.69 | 26.12 | 11.84 | |||||
EBITDA, 1 Yr. Growth % | -0.38 | -95.76 | 3.33K | 29.81 | -3.34 | |||||
EBITA, 1 Yr. Growth % | 0.24 | -133.79 | -579.39 | 35.35 | -7.44 | |||||
EBIT, 1 Yr. Growth % | 1.76 | -135.34 | -561.3 | 32.38 | -11.61 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | 3.32 | -239.71 | -237.23 | 26.21 | -63.37 | |||||
Net Income, 1 Yr. Growth % | 3.32 | -239.71 | -237.23 | 26.21 | -63.37 | |||||
Normalized Net Income, 1 Yr. Growth % | 2.91 | -137.92 | -532.95 | 31.29 | -13.17 | |||||